Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Haemonetics (HAE) Shares Repurchased (2018 - 2025)

Haemonetics has reported Shares Repurchased over the past 9 years, most recently at $150.0 million for Q1 2025.

For Q1 2025, Shares Repurchased changed N/A year-over-year to $150.0 million; the TTM value through Dec 2025 reached $150.0 million, changed N/A, while the annual FY2025 figure was $225.0 million, N/A changed from the prior year.
Shares Repurchased for Q1 2025 was $150.0 million at Haemonetics, up from $50.0 million in the prior quarter.
Over five years, Shares Repurchased peaked at $150.0 million in Q1 2025 and troughed at $150.0 million in Q1 2025.